Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Xgeva 60 mg PFS
Manufacturer/Marketed By : Dr Reddy'S Laboratories Ltd
$326.24 $274.04
Sidmex Inovia offers bulk export supply of Xgeva 60 mg PFS (Denosumab 60 mg) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain...
Denosumab 60 mg
Active Pharmaceutical Ingredient
Xgeva 60 mg PFS
$326.24
$274.04
Sidmex Inovia offers bulk export supply of Xgeva 60 mg PFS (Denosumab 60 mg) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.
Documents, cold-chain shipping and tenders: see our Export FAQ.
Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada
Related products we supply: Xgeva 120 mg PFS
Xgeva 60 mg PFS is an innovative treatment designed for individuals at elevated risk of bone fractures due to osteoporosis, particularly in men and postmenopausal women who haven't seen success with other osteoporosis medications. This powerful formulation is also effective for men diagnosed with prostate cancer and women undergoing breast cancer therapies that lead to bone density loss. By inhibiting the activity of osteoclasts, the cells responsible for bone breakdown, Xgeva helps maintain bone strength and reduce the likelihood of fractures. In addition to its primary uses, this medication is crucial for patients dealing with bone cancer and multiple myeloma, as it significantly lowers the risk of skeletal-related events. However, it's essential to be aware of potential side effects, including risk of hypocalcemia and osteonecrosis of the jaw, which necessitates monitoring during treatment. Xgeva 60 mg PFS provides a vital solution for those struggling with severe bone health issues, enhancing their quality of life through stronger bones and reduced fracture risk. Always consult a healthcare professional to determine if Xgeva is the right choice for your specific condition and to discuss any necessary precautions.
Active Pharmaceutical Ingredient
Uses
• Xgeva 60 mg pfs is utilized in the management of osteoporosis in men and postmenopausal women. This condition is characterized by decreased bone density, which increases the risk of fractures. For patients who are at high risk and have not seen improvement with other osteoporosis treatments, Xgeva 60 mg pfs can offer a valuable therapeutic option. Its use helps strengthen bones and reduce the likelihood of fractures in these vulnerable populations.
• The medicine is also effective for treating osteolytic bone metastases in patients with solid tumors, specifically in men with prostate cancer and women with breast cancer. These patients often experience significant bone loss due to their cancer treatments. By administering Xgeva 60 mg pfs, healthcare providers aim to mitigate this bone loss and enhance the overall quality of life for these individuals. This treatment helps maintain bone integrity during cancer therapy.
• Xgeva 60 mg pfs plays a critical role in patients who are undergoing treatment that may lead to bone complications. It is particularly beneficial for those whose cancer therapies can cause osteolytic lesions, which weaken bones. By using Xgeva 60 mg pfs, clinicians can help prevent skeletal-related events in these patients. This proactive approach is crucial in managing bone health while patients receive cancer treatment.
• In addition to its primary uses, Xgeva 60 mg pfs may be indicated for patients at risk of developing skeletal-related events due to their underlying conditions. This includes individuals with certain types of cancer that affect bone health. The medication supports bone strength and may reduce the incidence of complications related to bone fragility. Thus, Xgeva 60 mg pfs is an essential part of the treatment strategy for maintaining bone health in at-risk populations.
Benefits
Xgeva 60 mg PFS has been shown to be effective in reducing the risk of fractures in patients with osteoporosis and increasing bone density and strength, resulting in a lower risk of fractures in the spine, hip, and other bones. Xgeva 60 mg is effective in reducing the risk of fractures in patients with bone metastases (spread of cancer to the bones).
Side Effects
Anti-cancer Drug Xgeva may cause some side effects. If you experience any of these side effects, contact your doctor as soon as possible. Your doctor may be able to suggest ways to manage or reduce the severity of these side effects.
Most Common Side Effects
• Arm or leg pain
• Joint pain
• Muscle or bone pain
• Constipation,
• Abdominal discomfort
• Hair loss
• Skin rash
• Tingling, pain, or numbness that moves down your leg
Common Side Effects
• Upper respiratory tract infection
• Frequent or painful urination, blood in urine, inability to hold urine



